Humanwell Healthcare Group's controlling shareholder boosts stake

Humanwell Healthcare Group Co., Ltd. announced that its controlling shareholder, Zhaoshang Life Science (Wuhan) Co., Ltd., has completed its share increase plan, acquiring an additional 32,644,497 A-shares between July 17, 2025, and December 22, 2025. This represents 2% of the company's total share capital, with a total investment of 654,171,500 yuan (excluding transaction fees).

The share increase by Zhaoshang Life Science and its concerted parties resulted in their combined control over the company's shares increasing from 26.30% to 28.30% of total share capital. This change triggered the 1% equity change threshold multiple times.

The company previously disclosed the plan on July 3, 2025, and reported the first 1% threshold trigger on September 2, 2025. The latest increase further solidifies Zhaoshang Life Science's position, raising its direct ownership from 7.84% to 9.00%. The company confirmed that the share increase plan has been fully implemented and complies with relevant regulations, without triggering a tender offer or altering the company's control structure.